ERBB2 and uterine cervix neoplasm: The findings of "conversion to positive" in cells of recurrent cervical tumors showed by us and other authors [25,31] strongly suggest that expression of HER2 may have a role in tumor resistance and progression as shown in experimental models, and therefore its targeting in recurrent cervical cancer could have therapeutic value.